Gill Coombes

Gloucestershire Hospitals NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

11h-index2.0kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(24), Lung Cancer Treatments and Mutations(19), Advanced Breast Cancer Therapies(18), Breast Cancer Treatment Studies(7), Cancer Treatment and Pharmacology(7)

Publications46 total

Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity
International Journal of Rheumatic Diseases·2025
P125 Can musculoskeletal ultrasound assessment change management decisions in rheumatoid arthritis patients with moderate disease activity?
Lara D. Veeken·2024Open Access
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Judith M. Bliss(37), Roger A’Hern(26), Mitch Dowsett(24), Stephen Johnston(23), Alexandra Léary(21), Abigail Evans(21), Simone Detre(21), Catherine Harper‐Wynne(21), Nigel Bundred(21), Rashmita Sahoo(20), Margaret Hills(20), Benjamin P. Haynes(19), Ian Smith(19), Lucy Kilburn(9), Tom Treasure(7), Julian Peto(6), David Waller(5), James Entwisle(5), Mary Claire O’Brien(5), Gill Thomas(5)